Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
YARTEMLEA generated $32.2 million in Q2 gross revenue, and an eligible Medicare payment add-on takes effect October 1. Shares gained about 12% over 21 sessions.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Quarterly turnaround ⢠Negative equity ⢠Low cash OMER's strong quarterly profitability and cash generation improve its outlook, but negative equity, low cash, and historical losses keep balance-sheet risk elevated.
Price Behavior
Key Price Behavior Insights: ⢠Support Holding ⢠Sellers Active ⢠Breakout Needed Support Level: $17.15â$17.35 Resistance Level: $18.60â$19.00; stronger at $19.25â$19.40 OMER remains volatile and cautiously positioned last month, with $17.15â$17.35 support holding but a break below it bearish, while a sustained move above $19.25â$19.40 would improve the outlook.
Sentiment & News
Key News Insights: ⢠BlackRock Stake ⢠Golden Cross ⢠Momentum Focus BlackRock's 8.35% stake and bullish technical signals strengthen institutional and momentum interest in Omeros.
AI Summary
OMER's investment case has shifted to proving that YARTEMLEA can sustain $28M+ quarterly revenue and positive cash flow, which could accelerate deleveraging, but its single-product concentration and $297M debt load make any adoption or reimbursement shortfall highly consequential.
Description
Omeros Corporation is a commercial-stage biopharmaceutical company that develops small-molecule and protein therapeutics for inflammation, complement-mediated disorders, immune-related cancers, and addictive or compulsive disorders. Its pipeline spans late-stage assetsâmost notably a MASP-2 antibody that has completed a pivotal study for HSCTâTMA and is in Phase III for IgA nephropathy and aHUSâthrough earlier clinical programs and preclinical work on MASP-targeted small molecules, longer-acting antibodies, GPCR targets, and cell therapies. The company was incorporated in 1994 and is headquartered in Seattle, Washington.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Sep 24 | Oct 1 | OMER | Omeros Corporation | YARTEMLEA generated $32.2 million in Q2 gross revenue, and an eligible Medicare payment add-on takes effect October 1. Shares gained about 12% over 21 sessions. | Closed | -8.3% |
| Dec 29 | Jan 5 | OMER | Omeros Corporation | Omeros Corporation is a high-conviction hot idea driven by the transformative FDA approval of YARTEMLEAÂŽ (first approved treatment for TA-TMA), an 80%+ stock surge to 12-month highs, strategic capital infusion via license deal with Novo Nordisk, and strong near-term commercial launch prospects starting 2026. | Closed | -7.1% |